1. iMATCH: an integrated modular assembly system for therapeutic combination high-capacity adenovirus gene therapy
- Author
-
Alfred Zippelius, Nicole Kirchhammer, Andreas Plückthun, Melanie Grove, Fabian Weiss, Markus Schmid, Patrick C. Freitag, Nina Schumacher, Dominik Brücher, Urs F. Greber, Corina Keller, Jatina Schumacher, Jonas Kolibius, Sheena N. Smith, University of Zurich, and Plückthun, Andreas
- Subjects
0301 basic medicine ,gutless adenovirus ,lcsh:QH426-470 ,medicine.medical_treatment ,Genetic enhancement ,helper-dependent adenovirus ,Computational biology ,Vectors in gene therapy ,Biology ,Genome ,03 medical and health sciences ,0302 clinical medicine ,gene vectors ,1311 Genetics ,PD-1 ,10019 Department of Biochemistry ,1312 Molecular Biology ,Genetics ,medicine ,lcsh:QH573-671 ,Molecular Biology ,Gene ,Cloning ,lcsh:Cytology ,IL-2 ,Immunotherapy ,gene therapy ,10124 Institute of Molecular Life Sciences ,lcsh:Genetics ,030104 developmental biology ,Capsid ,IL-12 ,1313 Molecular Medicine ,030220 oncology & carcinogenesis ,Helper virus ,high-capacity vectors ,570 Life sciences ,biology ,Molecular Medicine ,cancer therapy ,Original Article ,immunotherapy - Abstract
Adenovirus-mediated combination gene therapies have shown promising results in vaccination or treating malignant and genetic diseases. Nevertheless, an efficient system for the rapid assembly and incorporation of therapeutic genes into high-capacity adenoviral vectors (HCAdVs) is still missing. In this study, we developed the iMATCH (integrated modular assembly for therapeutic combination HCAdVs) platform, which enables the generation and production of HCAdVs encoding therapeutic combinations in high quantity and purity within 3 weeks. Our modular cloning system facilitates the efficient combination of up to four expression cassettes and the rapid integration into HCAdV genomes with defined sizes. Helper viruses (HVs) and purification protocols were optimized to produce HCAdVs with distinct capsid modifications and unprecedented purity (0.1 ppm HVs). The constitution of HCAdVs, with adapters for targeting and a shield of trimerized single-chain variable fragment (scFv) for reduced liver clearance, mediated cell- and organ-specific targeting of HCAdVs. As proof of concept, we show that a single HCAdV encoding an anti PD-1 antibody, interleukin (IL)-12, and IL-2 produced all proteins, and it led to tumor regression and prolonged survival in tumor models, comparable to a mixture of single payload HCAdVs in vitro and in vivo. Therefore, the iMATCH system provides a versatile platform for the generation of high-capacity gene therapy vectors with a high potential for clinical development., Graphical Abstract, The iMATCH platform enables an efficient assembly of up to four orthogonal expression cassettes on a single plasmid from which high-capacity adenoviral vectors can be generated within 3 weeks in unprecedented purity. iMATCH vectors encoding immunotherapeutic combinations led to tumor regression and prolonged survival, comparable to mixtures of single payload HCAdVs.
- Published
- 2021